Karuna Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2018 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Karuna Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2018 to Q4 2023.
  • Karuna Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2023 was -$114M, a 49.4% decline year-over-year.
  • Karuna Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2023 was -$434M, a 56.9% decline year-over-year.
  • Karuna Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$434M, a 56.9% decline from 2022.
  • Karuna Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$276M, a 92.2% decline from 2021.
  • Karuna Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$144M, a 110% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2023 -$434M -$114M -$37.6M -49.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-22
Q3 2023 -$396M -$119M -$42.2M -54.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 -$354M -$103M -$38.2M -58.9% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-03
Q1 2023 -$316M -$97.6M -$39.4M -67.6% Jan 1, 2023 Mar 31, 2023 10-Q 2023-08-03
Q4 2022 -$276M -$76.2M -$48.3M -173% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-22
Q3 2022 -$228M -$77M -$26M -51.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$202M -$64.9M -$30.5M -88.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$172M -$58.2M -$27.7M -90.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-08-03
Q4 2021 -$144M -$28M -$3.95M -16.5% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-22
Q3 2021 -$140M -$50.9M -$32.1M -170% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$108M -$34.4M -$17.4M -102% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$90.4M -$30.5M -$21.8M -252% Jan 1, 2021 Mar 31, 2021 10-Q 2022-08-08
Q4 2020 -$68.6M -$24M -$16.2M -209% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-23
Q3 2020 -$52.3M -$18.8M -$9.8M -108% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$42.5M -$17M -$1.91M -12.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$40.6M -$8.66M +$3.35M +27.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-08-05
Q4 2019 -$44M -$7.77M +$553K +6.64% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 -$44.5M -$9.04M -$2.8M -44.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$41.7M -$15.1M -$14.6M -2709% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 -$27.1M -$12M -$9.6M -399% Jan 1, 2019 Mar 31, 2019 10-Q 2020-08-05
Q4 2018 -$17.5M -$8.33M Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 -$6.24M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$539K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 -$2.41M Jan 1, 2018 Mar 31, 2018 10-Q 2019-08-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.